Eron JJ, et al. - In an open-label, single-arm, multicentre, phase 3b trial at 26 outpatient clinics, researchers assessed 55 candidates between Feb 1, and Nov 3, 2016 to evaluate the safety, efficiency, and pharmacokinetics of regimen (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) in HIV-infected adults with end-stage renal disease on chronic haemodialysis. They found grade 1/grade 2 levels of adverse conflicts. Among them, nausea was noted as the most common treatment-related adverse impact. They also observe some grade 3 or higher adverse events like anemia, osteomyelitis, and hypertension etc, in 2 subjects only. Hence, this regimen was considered a tolerable and convenient treatment option for HIV-1 infection in adults with end-stage renal disease on chronic haemodialysis.